GlaxoSmithKline Pakistan Limited (PSX: GLAXO) delivered a stellar financial performance for the nine months ended September 30, 2025, with consolidated profit after tax skyrocketing 74.03% to Rs. 6.23 billion, up from Rs. 3.58 billion in the same period last year.
The standout feature of the period was a dramatic transformation in profitability, driven not by top-line growth but by cost management. While revenue from contracts saw a modest 2.03% increase to Rs44.49 billion, the cost of sales plummeted by 16.11% to Rs28.57 billion. This strategic achievement propelled gross profit to an impressive Rs15.92 billion, a 66.81% surge. The company continued its growth investments, with selling and marketing expenses rising 20.34% and administrative expenses up 11.15%. These were more than compensated for by the gross profit expansion, leading to a 79.32% leap in operating profit to Rs10.48 billion. The bottom line was further supported by a 29.06% reduction in finance charges.
Key Financial Highlights (9MFY25):
-
Earnings Per Share (EPS):Â Jumped to Rs. 19.57 from Rs. 11.25.
-
Revenue:Â Saw a modest increase of 2.03% to Rs. 44.49 billion.
-
Gross Profit:Â Soared 66.81% to Rs. 15.92 billion, highlighting exceptional margin expansion.
-
Operating Profit:Â Surged 79.32% to Rs. 10.48 billion.
-
Profit Before Tax:Â Grew an impressive 84.59% to Rs. 10.26 billion.
